Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
One example of a patient-facing app in Biogen’s portfolio is Cleo, an app for MS patients which the group launched in 2018. “An MS patient would typically meet their neurologist only twice a ...
Biogen also has a biosimilars segment producing generic drugs with a 4% YoY revenue growth of $202 million in 2024. Tecfidera and Vumerity are treatments for multiple sclerosis (MS). Its MS segment is ...
Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now ...
Biogen also has a biosimilars segment producing generic drugs with a 4% YoY revenue growth of $202 million in 2024. Tecfidera and Vumerity are treatments for multiple sclerosis (MS). Its MS ...
Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday agreed ...
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
With a market cap of $20.6 billion, Biogen specializes in treatments for conditions such as multiple sclerosis (MS), Alzheimer’s disease, spinal muscular atrophy, and other neurological disorders.
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...